HLA ligandome tumor antigen discovery for personalized vaccine approach

Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usu...

Full description

Bibliographic Details
Main Authors:	Rammensee, Hans-Georg, Singh-Jasuja, Harpreet
Format:	Online
Language:	English
Published:	Informa Healthcare 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821395/

id	pubmed-3821395
recordtype	oai_dc
spelling	pubmed-38213952013-11-11 HLA ligandome tumor antigen discovery for personalized vaccine approach Rammensee, Hans-Georg Singh-Jasuja, Harpreet Review Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usually not used in the adult organism. The search for cancer-associated antigens shared by many patients with a particular cancer has yielded a number of hits used in clinical vaccination trials with indication of survival benefit. Targeting cancer-specific antigens, which are exclusively expressed on cancer cells and not on normal cells, holds the promise for much better results and perhaps even a cure. Such antigens, however, may specifically appear in very few patients or may be mutated appearing just in one patient. Therefore, to target these in a molecularly defined way, the approach has to be individualized. Informa Healthcare 2013-10 2013-10-04 /pmc/articles/PMC3821395/ /pubmed/24090147 http://dx.doi.org/10.1586/14760584.2013.836911 Text en © Informa Healthcare
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Rammensee, Hans-Georg Singh-Jasuja, Harpreet
spellingShingle	Rammensee, Hans-Georg Singh-Jasuja, Harpreet HLA ligandome tumor antigen discovery for personalized vaccine approach
author_facet	Rammensee, Hans-Georg Singh-Jasuja, Harpreet
author_sort	Rammensee, Hans-Georg
title	HLA ligandome tumor antigen discovery for personalized vaccine approach
title_short	HLA ligandome tumor antigen discovery for personalized vaccine approach
title_full	HLA ligandome tumor antigen discovery for personalized vaccine approach
title_fullStr	HLA ligandome tumor antigen discovery for personalized vaccine approach
title_full_unstemmed	HLA ligandome tumor antigen discovery for personalized vaccine approach
title_sort	hla ligandome tumor antigen discovery for personalized vaccine approach
description	Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usually not used in the adult organism. The search for cancer-associated antigens shared by many patients with a particular cancer has yielded a number of hits used in clinical vaccination trials with indication of survival benefit. Targeting cancer-specific antigens, which are exclusively expressed on cancer cells and not on normal cells, holds the promise for much better results and perhaps even a cure. Such antigens, however, may specifically appear in very few patients or may be mutated appearing just in one patient. Therefore, to target these in a molecularly defined way, the approach has to be individualized.
publisher	Informa Healthcare
publishDate	2013
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821395/
_version_	1612024711215054848

HLA ligandome tumor antigen discovery for personalized vaccine approach

Similar Items